Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919].

IF 4.5 2区医学 Q1 ONCOLOGY

Lung Cancer Pub Date : 2024-11-01 DOI:10.1016/j.lungcan.2024.108000

Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, Stephen V Liu, Barbara Melosky, Devin Abrahami, Benjamin Li, Despina Thomaidou, Kirsten Duncan, Stan Krulewicz, Martin Rupp, Jessica J Lin

引用次数: 0

查看原文本刊更多论文

第二代和第三代 ALK 酪氨酸激酶抑制剂治疗 ALK 阳性晚期非小细胞肺癌的真实世界治疗排序和有效性"[Lung Cancer 195 (2024) 107919]的更正。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lung Cancer 医学-呼吸系统

CiteScore

9.40

自引率

3.80%

发文量

407

审稿时长

25 days

期刊介绍： Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.